J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting

 J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting

J&J Pauses Dosing of COVID-19 Vaccine Due to Blood Clotting

Shots:

  • J&J temporarily pause the use of the COVID-19 vaccine in the US, following recommended of the CDC and FDA. The review data involves six reported cases of a rare and severe type of blood clot in the US after receiving the J&J vaccine
  • The pause is due to the unusual clotting in 6 women aged 18-48 with symptoms occurring in 6-13 days after vaccination, in combination with reduced platelet counts. Additionally, J&J delay the rollout of the vaccine in the EU and pause vaccinations in all COVID-19 vaccine clinical trials
  • The similar blood clot problem seen in AstraZeneca’s COVID 19 vaccine, as reported by several EU countries which prompted curbs to its use

Source 1 , Source 2 to­ read full press release/ article | Ref: J&J | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post